Nano-carrier DMSN for effective multi-antigen vaccination against SARS-CoV-2

Peng Sun,Bingsheng Cheng,Jiaxi Ru,Xiaoyan Li,Guicun Fang,Yinli Xie,Guangjiang Shi,Jichao Hou,Longwei Zhao,Lipeng Gan,Lina Ma,Chao Liang,Yin Chen,Zhiyong Li

DOI: https://doi.org/10.1186/s12951-023-02271-w

IF: 10.2

2024-01-03

Journal of Nanobiotechnology

Abstract:Abstract The pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has had a profound impact on the global health and economy. While mass vaccination for herd immunity is effective, emerging SARS-CoV-2 variants can evade spike protein-based COVID-19 vaccines. In this study, we develop a new immunization strategy by utilizing a nanocarrier, dendritic mesoporous silica nanoparticle (DMSN), to deliver the receptor-binding domain (RBD) and conserved T-cell epitope peptides (DMSN-P-R), aiming to activate both humoral and cellular immune responses in the host. The synthesized DMSN had good uniformity and dispersion and showed a strong ability to load the RBD and peptide antigens, enhancing their uptake by antigen-presenting cells (APCs) and promoting antigen delivery to lymph nodes. The DMSN-P-R vaccine elicited potent humoral immunity, characterized by highly specific RBD antibodies. Neutralization tests demonstrated significant antibody-mediated neutralizing activity against live SARS-CoV-2. Crucially, the DMSN-P-R vaccine also induced robust T-cell responses that were specifically stimulated by the RBD and conserved T-cell epitope peptides of SARS-CoV-2. The DMSN demonstrated excellent biocompatibility and biosafety in vitro and in vivo, along with degradability. Our study introduces a promising vaccine strategy that utilizes nanocarriers to deliver a range of antigens, effectively enhancing both humoral and cellular immune responses to prevent virus transmission.

biotechnology & applied microbiology,nanoscience & nanotechnology

What problem does this paper attempt to address?

### Problems the Paper Aims to Solve

This paper aims to address the following issues:

1. **Limited effectiveness of existing vaccines against variants**: Although large-scale vaccination is crucial for establishing herd immunity, emerging SARS-CoV-2 variants of concern (VOCs) can evade the spike protein-based COVID-19 vaccines, leading to limited effectiveness of existing vaccines.

2. **Insufficient immune response**: Some patients, due to a lack of B cells or antibodies, are unable to generate specific humoral immune responses, putting them at risk of severe illness. Therefore, there is a need to develop a vaccine that is not affected by variants and can induce a cellular immune response.

To tackle these challenges, the research team developed a new immunization strategy using mesoporous silica nanoparticles (DMSN) as carriers to deliver the receptor-binding domain (RBD) and conserved T-cell epitope peptides (DMSN-P-R) to activate the host's humoral and cellular immune responses. Experimental results show that the DMSN-P-R vaccine can effectively induce a strong humoral immune response with significant neutralizing activity and also stimulate a robust T-cell response. Additionally, DMSN demonstrated good biocompatibility and biosafety both in vivo and in vitro. These results suggest that the nanoparticle-based vaccine strategy has great potential in preventing virus transmission.